A carregar...
t-Darpp overexpression in HER2-positive breast cancer confers a survival advantage in lapatinib
Drug resistance is a major barrier to successful cancer treatment. For patients with HER2-positive breast cancer who initially respond to therapy, the majority develop resistance within one year of treatment. Patient outcomes could improve significantly if we can find and exploit common mechanisms o...
Na minha lista:
| Publicado no: | Oncotarget |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Impact Journals LLC
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4741754/ https://ncbi.nlm.nih.gov/pubmed/26430732 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|